Caladrius

CLBS NASDAQ
2.890
+0.090
+3.21%
After Hours: 2.890 0 0.00% 16:00 07/19 EDT
Open
2.850
Prev Close
2.800
High
2.990
Low
2.850
Volume
85.66K
Avg Vol (3M)
42.80K
52 Week High
6.83
52 Week Low
2.160
% Turnover
0.83%
Market Cap
30.00M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Caladrius CLBS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
MORE >

Recently

Name
Price
%Change